XORTX Therapeutics Net Worth

XORTX Therapeutics Net Worth Breakdown

  XRTX
The net worth of XORTX Therapeutics is the difference between its total assets and liabilities. XORTX Therapeutics' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of XORTX Therapeutics' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. XORTX Therapeutics' net worth can be used as a measure of its financial health and stability which can help investors to decide if XORTX Therapeutics is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in XORTX Therapeutics stock.

XORTX Therapeutics Net Worth Analysis

XORTX Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including XORTX Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of XORTX Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform XORTX Therapeutics' net worth analysis. One common approach is to calculate XORTX Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares XORTX Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing XORTX Therapeutics' net worth. This approach calculates the present value of XORTX Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of XORTX Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate XORTX Therapeutics' net worth. This involves comparing XORTX Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into XORTX Therapeutics' net worth relative to its peers.
To determine if XORTX Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding XORTX Therapeutics' net worth research are outlined below:
XORTX Therapeutics generated a negative expected return over the last 90 days
XORTX Therapeutics has high historical volatility and very poor performance
XORTX Therapeutics has some characteristics of a very speculative penny stock
Net Loss for the year was (2.16 M) with profit before overhead, payroll, taxes, and interest of 0.
XORTX Therapeutics currently holds about 13.42 M in cash with (6.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.03, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
XORTX Therapeutics has a frail financial position based on the latest SEC disclosures
XORTX Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in XORTX Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to XORTX Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
29th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

Follow XORTX Therapeutics' market capitalization trends

The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.34 M.
XORTX Therapeutics time-series forecasting models is one of many XORTX Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary XORTX Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

XORTX Therapeutics Earnings per Share Projection vs Actual

XORTX Therapeutics Corporate Management

MD MBAChief OfficerProfile
MBA DVMChief OfficerProfile
Charlotte MayCorporate SecretaryProfile
MRCP MDChief OfficerProfile
David MacDonaldConsultant OperationsProfile
Nick RigopoulosDirector CommunicationsProfile

Already Invested in XORTX Therapeutics?

The danger of trading XORTX Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of XORTX Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than XORTX Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile XORTX Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.